Screener / SEC EDGAR /CIK 0000851520 /10-K filed Feb 27, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Industrials · Management Consulting Services

Exponent Inc EXPO

Compare with peers Embed
SEC comment letters, last 20 years

3 reviews of EXPO's filings by SEC staff

UPLOAD and CORRESP
Reviews 3 latest letter Oct 17, 2023
Questions asked 5 each answered in the company's own letter
No closing letter 0 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 4 UPLOAD
  2. 2. Questions in them 5 numbered comments
  3. 3. Company replies 4 CORRESP
  4. 4. Reviews closed 3 of 3 closing letter

Half the closed reviews took 31 days or less from the first letter to the closing letter.

Form 10-K for the Fiscal Year Ended December 30, 2022

2023-10-17 to 2024-01-10 · 3 questions · 2 letters from the SEC, 2 from the company
Review closed 2024-01-10
RevenueNon-GAAP measuresResults discussion (MD&A)
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations · Non-GAAP Financial Measures, page 31
SEC asked (1)
You state on page 46 that “[a]ny mark-up on reimbursable expenses is included in revenues before reimbursements.” Please tell us how you determined that excluding the reimbursable expenses from the denominator of your “EBITDA as a % of revenues before reimbursements” calculation does not result in an individually tailored revenue recognition.
Rest of the question

Refer to Question 100.04 of the Non-GAAP Financial Measures Compliance and Disclosure Interpretations.

EXPO answered
We acknowledge the Staff’s comment and respectfully advise the Staff that we believe our presentation of EBITDA as a % of revenues before reimbursements does not result in an individually tailored recognition and measurement principle that causes the presentation of non-GAAP measures to be misleading. The mark up on reimbursable expenses described on page 46 of the Form 10-K is a service fee that we charge our clients to cover the costs and risks associated with processing reimbursable expenses on behalf of our clients.
Rest of the answer

The costs being covered by this service fee include legal, contracting, purchasing, insurance, accounts payable, billing, and collections. While these costs are incurred in relation to the reimbursable expenses, they are not reimbursable expenses. Actual reimbursable expenses are excluded from both EBITDA (the denominator) and revenue before reimbursements (the numerator) in our presentation of EBITDA as a % of revenues before reimbursements. All the costs associated with processing and collecting reimbursable expenses are included in EBITDA. Revenue for this service fee is recognized as the services are being performed and therefore no adjustments are being made to our revenue recognition. Therefore, we believe that including this service fee in the denominator (revenue before reimbursements) of our EBITDA as a percentage of revenue before reimbursements is appropriate and does not result in an individually tailored recognition and measurement principle that causes the presentation of non-GAAP measures to be misleading.

Read in the reply
In its next report

First report after the company's reply of Oct 30, 2023: 10-Q filed Nov 3, 2023 ↗, against the 10-Q filed Aug 7, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Business Outlook
SEC asked (2)
You provide a range of forward-looking EBITDA as a % of revenues before reimbursements, a non-GAAP financial measure, for the third quarter of fiscal year 2023 and full fiscal year 2023. Please provide a reconciliation to the most directly comparable GAAP financial measure or a statement that providing such reconciliation requires unreasonable efforts.
Rest of the question

Refer to Item 10(e)(1)(i)(B) of Regulation S-K and Question 102.10(b) of the Non-GAAP Financial Measures Compliance and Disclosure Interpretations.

EXPO answered
We acknowledge the Staff’s comment and [included in our earnings release dated October 26th, 2023 and] will include, in all future filings that provide forward-looking guidance, a statement that providing a reconciliation of forward-looking EBITDA as a % of revenues before reimbursements to the most directly comparable GAAP financial measure, net income, requires unreasonable efforts.
Read in the reply
In its next report

First report after the company's reply of Oct 30, 2023: 10-Q filed Nov 3, 2023 ↗, against the 10-Q filed Aug 7, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations · Non-GAAP Financial Measures, page 31
SEC asked
We note your response to prior comment 1. It appears to us that you present “EBITDA as a % of revenues before reimbursements” ratio based on revenues before reimbursements as opposed to total revenues. Please tell us how presenting this measure as though you are an agent in these revenue generating transactions when gross presentation as a principal is required by GAAP does not represent an individually tailored
Rest of the question

revenue recognition method. Refer to Question 100.04 of the Non-GAAP Financial Measures Compliance and Disclosure Interpretations.

EXPO answered
We acknowledge the Staff’s comment and respectfully advise the Staff that we believe our presentation of EBITDA as a percentage of revenues before reimbursements does not result in an individually tailored recognition and measurement method that causes the presentation of non-GAAP measures to be misleading.

Question 100.04 relates to “non-GAAP adjustments that have the effect of changing the recognition and measurement principles required to be applied in accordance with GAAP.” Our calculation of EBITDA as a percentage of revenue before reimbursements does not represent a substitute for
Rest of the answer

amounts recognized and measured over time on an accrual basis in accordance with GAAP and our accounting policies and methods. The calculation also does not have the effect of changing the pattern of revenue recognition.

On our consolidated statement of net income, we present revenues in accordance with GAAP, showing both components: (i) revenues before reimbursements and (ii) reimbursements.

Reimbursements, including those related to travel and other out-of-pocket expenses, and other similar third-party costs such as the cost of materials and certain subcontracts, are included as a component of revenues, and an equivalent amount of reimbursable expenses are included as a component of operating expenses. In addition, changes in the reimbursements component of revenues are not indicative of growth or decline in our business due to the variability of the travel and other out-of-pocket expenses included in this component of revenue. We believe that EBITDA as a percentage of total revenues would not provide a meaningful measure of profitability due to (i) the offsetting nature of reimbursements being included in revenues with a corresponding and identical expense and (ii) the variability in the reimbursements component of revenues.

The revenues before reimbursements component of revenues is used by management to evaluate financial results, develop budgets, and determine employee compensation. This component of revenue is the most meaningful metric to measure the growth or decline in our business, as the reimbursement component of revenues is not indicative of growth or decline of our business. Management provides guidance to investors regarding our growth in revenue before reimbursements which provides a meaningful comparison of past, present, and future operating results. EBITDA as a percentage of revenue before reimbursements is used by management, analysts, and investors to evaluate the profitability of the business. This metric is also one of the metrics used to determine CEO compensation.

Accordingly, we believe that presenting EBITDA as a percentage of revenue before reimbursements, when viewed in combination with our revenues calculated in accordance with GAAP, provides investors with a more complete and useful presentation of our financial performance. Given the reasons discussed above and our consistent presentation of EBITDA as a percentage of revenue before reimbursements in the past, we do not believe that the presentation is misleading to investors.

Read in the reply
In its next report

First report after the company's reply of Nov 20, 2023: 10-K filed Feb 23, 2024 ↗, against the 10-K filed Feb 24, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2024-01-10

Form 10-K for the Fiscal Year Ended January 3, 2020

2020-11-17 to 2020-12-04 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2020-12-04
SegmentsResults discussion (MD&A)
Financial Statements · Note 17. Segment Reporting, page 60
SEC asked
Please revise your footnote disclosure to discuss in greater detail the types of amounts included in the corporate operating expense, capital expenditures and depreciation and amortization line items of your segment reconciliations.
Rest of the question

Also, revise your management's discussion and analysis section to discuss the business reasons for changes between periods in each segment's operating income and amounts in the corporate operating expense line item. In circumstances where there is more than one business reason for the change, please quantify the incremental impact of each individual business reason discussed on the overall change in the line item. Refer to Item 303(a)(3) of Regulation S- K and SEC Release No. 33-8350.

EXPO answered
We acknowledge the Staff’s comment and in an effort to further enhance our disclosure and in response to the Staff’s comment, we will revise our footnote disclosure in future filings, including our Form 10-K for the fiscal year ending January 1, 2021, to discuss in greater detail the types of amounts included in the corporate operating expense, capital expenditures and depreciation and amortization line items of our segment reconciliations, to the extent applicable, consistent with the following:

Revenues

Fiscal Years

(In thousands)

2019

2018

2017

Engineering and Other
Rest of the answer

Scientific

$

339,796

306,265

277,603

Environmental and Health

77,403

73,258

70,196

Total revenues

417,199

379,523

347,799

Operating Income

110,822

100,307

93,451

26,589

23,824

22,340

Total segment operating income

137,411

124,131

115,791

Corporate operating expense

(52,300

)

(32,675

(43,740

Total operating income

85,111

91,456

72,051

Capital Expenditures

4,675

4,528

3,648

104

199

218

Total segment capital expenditures

4,779

4,727

3,866

Corporate capital expenditures

17,511

12,654

859

Total capital expenditures

22,290

17,381

4,725

Depreciation and Amortization

4,827

4,435

4,449

206

171

179

Total segment depreciation and amortization

5,033

4,606

4,628

Corporate depreciation and amortization

1,773

1,686

1,657

Total depreciation and amortization

6,806

6,292

6,285

“Certain operating expenses are excluded from the Company’s measure of segment operating income. These expenses include the costs associated with our human resources, finance, information technology, and business development groups; the deferred compensation expense/benefit due to the change in value of assets associated with our deferred compensation plan; stock-based compensation associated with restricted stock unit and stock option awards; and the change in our allowance for contract losses and doubtful accounts.

Certain capital expenditures associated with the Company’s corporate cost centers and the related depreciation are excluded from the Company’s segment information. The significant increase in corporate capital expenditures during 2018 and 2019 was due to the land purchase and construction costs associated with our office and laboratory facilities in Natick, Massachusetts.”

Also, in future filings, to the extent applicable, we will revise our management’s discussion and analysis section to discuss the business reasons for changes between periods in each segment’s operating income and amounts in the corporate operating expense line item, quantifying the incremental impact of each individual business reason discussed on the overall change in the line item in circumstances where there is more than one business reason for the change, consistent with the following:

“The increase in operating income for our Engineering and Other Scientific segment during 2019 as compared to 2018 was due to an increase in revenues. The increase in revenues was due to an increase in billable hours and an increase in billing rates. We continued to see strong demand for our services related to product recalls, including assignments from the consumer products and automotive industries. Proactive services continued to expand as companies sought our interdisciplinary advice throughout the product life cycle, consistent with the increased importance placed on understanding how users interact with complex technologies.

The increase in operating income for our Environmental and Health segment during 2019 as compared to 2018 was due to an increase in revenues. The increase in revenues was due to an increase in billable hours and an increase in billing rates. The increase in billable hours was due to the expansion of our chemical regulation & food safety proactive services.

The increase in corporate operating expenses during 2019 as compared to 2018 was primarily due to an increase in deferred compensation expense. During 2019, deferred compensation expense increased $16,734,000, with a corresponding increase to other income, net, as compared to the prior year, due to the change in value of assets associated with our deferred compensation plan. This increase consisted of an increase in the value of plan assets of $12,834,000 during 2019 as compared to a decrease in the value of plan assets of $3,900,000 during 2018. The increase in corporate operating expenses was also due to an increase in travel and meals due to a firm-wide managers meeting held during 2019, an increase in stock-based compensation associated with restricted stock unit grants, and increases in expenses for our human resources, finance, information technology, and business development groups due to increases in technical full-time equivalent employees, investments in our corporate infrastructure and fiscal 2019 having one additional week of activity than fiscal 2018.

The increase in operating income for our Engineering and Other Scientific segment during 2018 as compared to 2017 was due to an increase in revenues. The increase in revenues was due to an increase in billable hours and an increase in billing rates. We continued to see strong demand from multinational companies for our scientific expertise and advice regarding their products. Safety concerns regarding energy storage systems drove increased demand for risk assessments in the consumer products, transportation, utility and medical device industries.

The increase in operating income for our Environmental and Health segment during 2018 as compared to 2017 was due to an increase in revenues. The increase in revenues was due to an increase in billable hours and an increase in billing rates. The increase in billable hours was due to the expansion of our chemical regulation & food safety proactive services.

The decrease in corporate operating expenses during 2018 as compared to 2017 was primarily due to a decrease in deferred compensation expense. During 2018, deferred compensation expense decreased $10,447,000, with a corresponding decrease to other income, net, as compared to the prior year, due to the change in value of assets associated with our deferred compensation plan. This decrease consisted of a decrease in the value of plan assets of $3,900,000 during 2018 as compared to an increase in the value of plan assets of $6,547,000 during 2017.”

Read in the reply
In its next report

First report after the company's reply of Nov 25, 2020: 10-K filed Feb 26, 2021 ↗, against the 10-K filed Feb 28, 2020 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2020-12-04

Form 10-K for the Fiscal Year Ended January 2, 2015

2015-08-17 to 2015-09-17 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2015-09-17
RevenueGoodwill and impairment
Note 1 – Summary of Significant Accounting Policies · Goodwill, page 41
SEC asked
We note that the two-step goodwill impairment test was not performed due to your conclusions based upon various qualitative factors. We further note the disclosure on page 22 regarding your expectations that one your major investigations will step-down from its elevated level of activity.
Rest of the question

Based upon statements made by your CEO in your July 21, 2015 earnings call, it appears that this major investigation is related to an oil spill in the Gulf and that the revenues from this project have ceased abruptly. Please tell us the reporting unit to which this investigation has been allocated and how the events related to this project impact your goodwill analysis.

EXPO answered
The investigation referred to on page 22 of our Form 10-K and also referred to in our July 21, 2015 earnings call is work performed in our Environmental & Earth

Sciences practice and our Ecological & Biological Sciences practice. Both of these reporting units (practices) are included in our Environmental and Health Segment.

The step-down in activity referred to for this project was considered in our annual goodwill analysis performed as of November 28, 2014, and did not change our conclusion that, after assessing the totality of the qualitative factors, it is more likely than not that the
Rest of the answer

fair value of each of these reporting units is greater than their respective carrying amounts. Although we were aware that the project was winding down, we anticipated a gradual slowdown. However, there was no indication of impairment of goodwill for these reporting units and therefore the two-step goodwill impairment test was not performed. The aggregate goodwill of approximately $4.0 million allocated to these reporting units originated from an acquisition in 1997. The revenue and net income for each of these reporting units have increased significantly since 1997 and the fair value of each of these reporting units significantly exceeded their net book value based on the last quantitative test as of November 26, 2010. As a point of reference, Exponent’s current market capitalization is approximately $1.1 billion as compared to the total net book value of $259.6 million, which includes goodwill totaling $8.6 million as of July 3, 2015.

With respect to the subsequent cessation of revenues from the project, we assessed and concluded that an interim triggering event did not occur. Because of the significant surplus of fair value over net book value in these reporting units, even taking into account the loss of the project margin, there is no change to our conclusion that it is not more likely than not that there is an impairment loss.

* * *

In addition, Exponent acknowledges the following:

· Exponent is responsible for the adequacy and accuracy of the disclosure in the filing;

· Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and

· Exponent will not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Read in the reply
In its next report

First report after the company's reply of Aug 24, 2015: 10-Q filed Nov 6, 2015 ↗, against the 10-Q filed Aug 7, 2015 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2015-09-17

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 11 letters filed since 2015-08-17. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/EXPO/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.